Level Four Advisory Services LLC Sells 25,668 Shares of Genmab A/S (NASDAQ:GMAB)

Level Four Advisory Services LLC cut its stake in shares of Genmab A/S (NASDAQ:GMAB - Free Report) by 60.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,620 shares of the company's stock after selling 25,668 shares during the period. Level Four Advisory Services LLC's holdings in Genmab A/S were worth $347,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of GMAB. EverSource Wealth Advisors LLC boosted its stake in Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock worth $26,000 after purchasing an additional 939 shares during the period. Lindbrook Capital LLC boosted its position in shares of Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock worth $39,000 after buying an additional 950 shares during the period. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock valued at $45,000 after buying an additional 1,051 shares in the last quarter. Cromwell Holdings LLC grew its holdings in shares of Genmab A/S by 656.8% during the fourth quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after buying an additional 2,496 shares in the last quarter. Finally, R Squared Ltd acquired a new position in Genmab A/S during the fourth quarter valued at $93,000. 7.07% of the stock is owned by hedge funds and other institutional investors.

Genmab A/S Stock Performance

Shares of NASDAQ GMAB traded up $0.42 during mid-day trading on Thursday, reaching $19.24. 1,715,372 shares of the company traded hands, compared to its average volume of 973,396. The company's fifty day moving average is $20.76 and its two-hundred day moving average is $21.71. Genmab A/S has a fifty-two week low of $18.48 and a fifty-two week high of $30.50. The stock has a market cap of $12.73 billion, a PE ratio of 11.06, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Remove Ads

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, topping analysts' consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. Research analysts forecast that Genmab A/S will post 1.45 earnings per share for the current year.

Analysts Set New Price Targets

GMAB has been the subject of a number of research reports. Leerink Partners upgraded Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price objective for the company in a research report on Thursday, February 13th. Sanford C. Bernstein downgraded shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday. Truist Financial dropped their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Finally, Leerink Partnrs raised shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 13th. One research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $41.33.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.